Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: Results of the REAL07 open-label, multicentre, phase 2 trial

The Lancet Oncology

Volumn 15, Issue 7, 2014, Pages 730-737

  Vitolo, Umberto ^a   Chiappella, Annalisa ^a   Franceschetti, Silvia ^b   Carella, Angelo Michele ^c   Baldi, Ileana ^d   Inghirami, Giorgio ^e,f   Spina, Michele ^g   Pavone, Vincenzo ^h   Ladetto, Marco ^e   Liberati, Anna Marina ⁱ   Molinari, Anna Lia ^j   Zinzani, Pierluigi ^k   Salvi, Flavia ^l   Fattori, Pier Paolo ^m   Zaccaria, Alfonso ⁿ   Dreyling, Martin ^o   Botto, Barbara ^a   Castellino, Alessia ^a   Congiu, Angela ^c   Gaudiano, Marcello ^e,f   Zanni, Manuela ^e   Ciccone, Giovannino ^a   Gaidano, Gianluca ^b   Rossi, Giuseppe ^p   more..

^a UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^b Amedeo Avogadro University   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^h Unit of Hematology and Hemopoietic Stem Cell Transplantation Ospedale Cardinale G Panico   (Italy)

ⁱ UNIVERSITY OF PERUGIA   (Italy)

^j Infermi Hospital   (Italy)

^k UNIVERSITY OF BOLOGNA   (Italy)

^l Divisione di Ematologia   (Italy)

^m DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

ⁿ SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^o LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^p Spedali Civili   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GRANULOCYTE COLONY STIMULATING FACTOR; LAMIVUDINE; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; PENTAMIDINE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; COLITIS; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GERIATRIC PATIENT; GERMANY; GRAM NEGATIVE INFECTION; HEPATITIS B; HUMAN; HUMAN TISSUE; INFECTION; ITALY; KIDNEY DISEASE; LARGE CELL LYMPHOMA; LEUKOPENIA; LIVER DYSFUNCTION; LYMPHADENOPATHY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RASH; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; THALIDOMIDE; VINCRISTINE;

EID: 84901391325     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70191-3     Document Type: Article

References (31)

1. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues 2008, IARC Press, Lyon. 4th edn.
2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
3. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008, 9:105-116.
4. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell Lymphoma. J Clin Oncol 2006, 24:3121-3127.
5. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005, 23:4117-4126.
6. Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 2013, 14:525-533.
7. Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 2013, 87:146-171.
8. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993, 329:987-994. The International Non-Hodgkin's Lymphoma Prognostic Factors Project.
9. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010, 28:2373-2380.
10. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
11. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-1947.
12. Huang JZ, Sanger WG, Greiner TC, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002, 99:2285-2290.
13. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103:275-282.
14. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009, 15:5494-5502.
15. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003, 100:9991-9996.
16. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359:2313-2323.
17. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:4952-4957.
18. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011, 22:1622-1627.
19. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011, 117:5058-5066.
20. Zinzani PL, Pellegrini C, Gandolfi L, et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk 2011, 11:462-466.
21. Zhang L, Qian Z, Cai Z, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009, 84:553-559.
22. Nowakowski GS, LaPlant B, Habermann TM, et al. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia 2011, 25:1877-1881.
23. Tilly H, Morschhauser F, Salles G, et al. Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia 2013, 27:252-255.
24. Chiappella A, Tucci A, Castellino A, et al. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: phase I study by the Fondazione Italiana Linfomi. Haematologica 2013, 98:1732-1738.
25. Barosi G, Carella A, Lazzarino M, et al. Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica 2005, 90:1236-1257.
26. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
27. Simon R Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
28. Wiernik PH, Lossos I, Tuscano J, et al. Preliminary results from a phase II study of lenalidomide monotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma. Blood 2006, 108:531. (abstr).
29. Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 2013, 27:1902-1909.
30. Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012, 13:716-723.
31. Nowakowski GS, LaPlant BR, Reeder C, et al. Combination of lenalidomide with R-CHOP (R2CHOP) is well-tolerated and effective as initial therapy for aggressive B-cell lymphomas-a phase II study. Blood 2012, 120:689. (abstr).